You searched for "infections"
Update: Non-infectious retinal vasculitis
2 December 2024
| Sofia Rokerya
|
EYE - Vitreo-Retinal
This review article summarises the update on non-infectious retinal vasculitis (RV). It is primarily classified based on the type of retinal vessels involved and further sub-classified as occlusive or nonocclusive. Clinically it can occur as an isolated ocular entity or...
Detecting muscle insertion position by ultrasound
The purpose of this study was to investigate the accuracy to locate muscle insertion positions before and after strabismus surgery using wide-field ultrasound biomicroscopy with the bag / balloon technique. Thirty-nine muscles of 22 adult patients aged 34.7 ±15.5 years...Ocular hypertension following intravitreal steroid injections: a comparative study between triamcinolone-acetonide and dexamethasone-implant
This was a retrospective observational study of steroid response following 1549 intravitreal steroid (TA and Dex) injections. One thousand and seventy-five eyes of 897 patients were reviewed. Glaucoma patients, glaucoma suspects, uveitis, trauma, and cases with less than one month...The ocular manifestations of COVID-19: an overview of current literature
Although respiratory symptoms are the most frequent manifestation of COVID-19, multi-organ involvement has been demonstrated, including ocular manifestations. The author investigates how the eye can be affected. The SARS-CoV-2 virus responsible for the COVID-19 pandemic has presented a significant public...Incidence and outcomes of endophthalmitis with in-house compounded intravitreal bevacizumab injections
1 December 2021
| Su Young
|
EYE - Vitreo-Retinal
|
IVI, In-house compounded, bevacizumab, compounding pharmacy, endophthalmitis
This multicentre study examining a five-year period from 2014 to 2018 evaluated the incidence rate and outcomes of endophthalmitis after intravitreal injection of in-house compounded bevacizumab. In-house compounded syringes were prepared in compounding pharmacy using sterile standard operating guidelines. All...
Intravitreal injection related endophthalmitis
1 April 2015
| Jaya Myneni
|
EYE - Vitreo-Retinal
This article reviews the incidence, clinical findings, risk factors, management and visual outcomes in intravitreal injection related endophthalmitis. Incidence of this complication is reported to be in the range of 0.038% to 0.065% (1 in 2000-3000 injections). Patients present typically...
Evisceration in India: demographic and clinical trends from a large multicentre cohort study
4 October 2023
| Su Young
|
EYE - Orbit
In this multicentre cohort study, the authors investigated a total of 2071 patients who underwent evisceration with primary implant placement over a six-year period at four tertiary eyecare centres in India. Out of 1,345,480 new ophthalmic presentations during the study...
Does intravitreal bevacizumab help in diabetic retinopathy related vitreous haemorrhage?
1 October 2017
| Efrosini Papagiannuli
|
EYE - Vitreo-Retinal
This retrospective, interventional case series, aimed to assess the effectiveness of intravitreal bevacizumab (IVB) in vitreous haemorrhage secondary to proliferative diabetic retinopathy. The primary outcome was the rate of vitrectomy (PPV) after IVB, with secondary outcomes the number of IVB...
Methotrexate and mycophenolate mofetil for non-infectious uveitis
1 February 2015
| Brian Ang
|
EYE - Vitreo-Retinal
This is the first reported randomised clinical trial comparing methotrexate versus mycophenolate mofetil (MMF) for the treatment of non-infectious intermediate uveitis, posterior uveitis or panuveitis. To be eligible for recruitment, patients had to be on ≥15mg oral prednisone and demonstrated...
Late stromal rejection in DALK
This case series reported on late stromal rejections in eyes after uncomplicated deep anterior lamellar keratoplasties (DALKs). Four eyes of three patients experienced episodes of isolated stromal rejection 33 to 46 months after surgically uncomplicated DALKs and a minimum of...Four year outcomes of macular degeneration treated with ranibizumab
1 February 2014
| Brian Ang
|
EYE - Vitreo-Retinal
The authors report on a retrospective study of neovascular age-related macular degeneration (AMD) patients treated with a variable ranibizumab dosing regimen over a period of four years (from January 2007 to December 2011). A total of 600 treatment naïve eyes...
Moorfields implementing a non-medical intravitreal injection service
28 March 2025
This highly sought after intravitreal injection course has had a national and global impact by enabling numerous institutions to establish their own non-medical delivered IVT injection services. With an increasing demand in treatment for people with eye conditions such as...